Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: A survey from the acute leukemia working party of EBMT
Hematopoietic stem cell transplantation (HSCT) is being increasingly explored as a treatment modality for older patients with acute lymphoblastic leukemia (ALL). Yet, concerns regarding the long term outcome of transplantation in older patients limit the wide spread applicability of this approach. In this analysis we set out to determine the outcome of ALL patients over the age of 60 who underwent reduced intensity HSCT. Herein, we present the experience of the acute leukemia working party (ALWP) of the EBMT in this age group. We analyzed a cohort of 142 patients transplanted in first remission with a median age of 62 (range 60-76 years) and a median follow-up period of 36 months post-transplant. At 3 years, overall survival (OS) and leukemia-free survival were 42% and 35%, respectively. Multivariate analyses identified cytomegalovirus (CMV) donor-recipient matching (CMV D+/R+) to be significantly associated with inferior OS. Patients transplanted from unrelated donors experienced increased grade II-IV acute graft versus host disease compared to those receiving grafts from matched related donors [Hazard ratio (HR) of 3.7, 95% confidence interval (CI), 1.75-7.8; p = 0.0005). Outcome was not impacted by Philadelphia chromosome status. A select subset of older ALL patients will benefit from extended survival and a disease free state following HSCT.
|Keywords||Acute lymphoblastic leukemia, Allogeneic hematopoietic cell transplantation, Cytomegalovirus, Elderly, Graft versus host disease|
|Persistent URL||dx.doi.org/10.18632/oncotarget.22934, hdl.handle.net/1765/103627|
Roth-Guepin, G. (Gabrielle), Canaani, J, Ruggeri, A, Labopin, M, Finke, J, Cornelissen, J.J, … Mohty, M. (2017). Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: A survey from the acute leukemia working party of EBMT. Oncotarget, 8(68), 112972–112979. doi:10.18632/oncotarget.22934